A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

To join this study, you need to be at least 18 years old and have a solid tumour that is advanced or has spread. Your cancer must also have a specific genetic change called a KRAS G12D mutation. In many cases, you would have already tried other standard cancer treatments, or those treatments might not be suitable for you. You also need to be generally well enough to take part, meaning you can carry out most of your daily activities without much difficulty.

There are certain reasons why someone might not be able to join. For example, if you've already had a treatment designed specifically for KRAS G12D mutations, or if you've had another type of cancer within the last year that could interfere with the study. You also wouldn't be able to join if you've had an organ transplant, have a serious uncontrolled medical problem, certain heart issues, or if your organs like your liver or kidneys aren't working well enough. The medical team will check all these details carefully.

If you decide to take part, you'll be given the new study drug, INCB161734, either on its own or in combination with other cancer treatments. This will involve regular visits to the clinic for medical check-ups, blood tests, and scans to monitor your health and how the treatment is affecting your cancer. These assessments help the doctors understand how safe the treatment is and if it's working. The exact number of visits and the duration of your participation will depend on the specific part of the study you are in and how you respond to the treatment. You will receive detailed information about your schedule if you join.